ALK Genomic Aberrations in NSCLC and Clinical Implications

被引：0
|
作者：
Hirsch, F. R. [1 ]
机构：
[1] Mt Sinai, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 11期
关键词：
Crizotinib; Ceritinib; Alectinib; Brigatinib; Lorlatinib; CHEMOTHERAPY; CRIZOTINIB;
D O I：
10.1016/j.jtho.2019.09.114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
I.17
引用
收藏
页码：S1163 / S1164
页数：3
相关论文
共 50 条
  • [21] ALK Inhibitors in the Treatment of ALK Positive NSCLC
    Khan, Muhammad
    Lin, Jie
    Liao, Guixiang
    Tian, Yunhong
    Liang, Yingying
    Li, Rong
    Liu, Mengzhong
    Yuan, Yawei
    FRONTIERS IN ONCOLOGY, 2019, 8
  • [22] Accumulation of genomic aberrations during clinical progression of medulloblastoma
    Andrey Korshunov
    Axel Benner
    Marc Remke
    Peter Lichter
    Andreas von Deimling
    Stefan Pfister
    Acta Neuropathologica, 2008, 116
  • [23] RT-PCR and IHC as the alternative methods for detection of ALK aberrations in NSCLC samples - The feasibility study
    Skronski, Michal
    Langfort, Renata
    Gizycka, Agata
    Giedronowicz, Dorota
    Jagus, Paulina
    Chorostowska-Wynimko, Joanna
    Langfort, Renata
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [24] Coexistence of driver aberrations in NSCLC patients including ALK/RET/ROS1 rearrangements.
    Bien-Willner, Gabriel Alejandro
    Yang, Dong
    Xia, Dianren
    Wang, Jixin
    Indiviglio, Sandra
    Renard, Jamie
    Miles, George
    Mambo, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Accumulation of genomic aberrations during clinical progression of medulloblastoma
    Korshunov, Andrey
    Benner, Axel
    Remke, Marc
    Lichter, Peter
    von Deimling, Andreas
    Pfister, Stefan
    ACTA NEUROPATHOLOGICA, 2008, 116 (04) : 383 - 390
  • [26] Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas
    Salaverria, Itziar
    Bea, Silvia
    Lopez-Guillermo, Armando
    Lespinet, Virginia
    Pinyol, Magda
    Burkhardt, Birgit
    Lamant, Laurence
    Zettl, Andreas
    Horsman, Doug
    Gascoyne, Randy
    Ott, German
    Siebert, Reiner
    Delsol, Georges
    Campo, Elias
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 140 (05) : 516 - 526
  • [27] Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.
    Shaw, Alice Tsang
    Mehra, Ranee
    Kim, Dong-Wan
    Felip, Enriqueta
    Chow, Laura Quan Man
    Camidge, D. Ross
    Tan, Daniel Shao-Weng
    Vansteenkiste, Johan F.
    Sharma, Sunil
    De Pas, Tommaso
    Wolf, Juergen
    Katayama, Ryohei
    Lau, Yi-Yang Yvonne
    Goldwasser, Meredith
    Boral, Anthony
    Engelman, Jeffrey A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Clinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions
    Yeh, Iwei
    de la Fouchardiere, Arnaud
    Pissaloux, Daniel
    Mully, Thaddeus W.
    Garrido, Maria C.
    Vemula, Swapna S.
    Busam, Klaus J.
    LeBoit, Philip E.
    McCalmont, Timothy H.
    Bastian, Boris C.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (05) : 581 - 591
  • [29] Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy
    Wiesner, Thomas
    Kutzner, Heinz
    Cerroni, Lorenzo
    Mihm, Martin C., Jr.
    Busam, Klaus J.
    Murali, Rajmohan
    PATHOLOGY, 2016, 48 (02) : 113 - 131
  • [30] Genomic and Epigenomic Aberrations in Esophageal Squamous Cell Carcinoma and Implications for Patients
    Lin, De-Chen
    Wang, Ming-Rong
    Koeffler, H. Phillip
    GASTROENTEROLOGY, 2018, 154 (02) : 374 - 389
12345